Compare MCS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCS | DRUG |
|---|---|---|
| Founded | 1935 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 873.2M | 778.4M |
| IPO Year | 1994 | 2020 |
| Metric | MCS | DRUG |
|---|---|---|
| Price | $28.04 | $51.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $32.25 | ★ $152.40 |
| AVG Volume (30 Days) | ★ 188.4K | 128.4K |
| Earning Date | 10-29-2026 | 08-17-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,458,000.00 | N/A |
| Revenue This Year | $14.64 | N/A |
| Revenue Next Year | $2.22 | N/A |
| P/E Ratio | $37.21 | ★ N/A |
| Revenue Growth | ★ 3.11 | N/A |
| 52 Week Low | $12.85 | $47.23 |
| 52 Week High | $32.42 | $123.75 |
| Indicator | MCS | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 41.28 |
| Support Level | $28.19 | $47.23 |
| Resistance Level | $28.89 | $55.78 |
| Average True Range (ATR) | 0.79 | 3.26 |
| MACD | 0.15 | 0.93 |
| Stochastic Oscillator | 62.17 | 58.25 |
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.